NCT05169489: A trial that was reported late by Regeneron Pharmaceuticals
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05169489 |
|---|---|
| Title | A Phase 1/2 Study of bbT369, a Dual Targeting CAR T Cell Drug Product With a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 24, 2022 |
| Completion date | Aug. 31, 2025 |
| Required reporting date | Aug. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 24, 2025 |
| Days late | None |